Neoplasms

All Conditions

Digestive System Diseases

Carcinoma

Peritoneal Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Abdominal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Peritoneal Diseases

Patients suffering from Peritoneal carcinomatoses from either CRC, gastric cancer or primary peritoneal malignancies

Patients suffering from CRC or gastric cancer without peritoneal carcinomatosis

Jens M Werner, MD

Monika Diehl-Bein

Pompiliu Piso, MD

Matthias Hornung, MD

Longitudinal Study of the Effect of Cytoreductive Surgery and HIPEC in Patients With Peritoneal Carcinomatoses

Cross-sectional and longitudinal analysis of cellular immune responses in the context of disease outcome.

Cross-sectional and longitudinal analysis of the microbiome in the context of disease outcome.

Analysis of renal function with respect of different HIPEC regimens

Identification of clinical surrogate parameters for outcome.

blood samples; stool samples; tumor samples; Peritoneal tissue

Longitudinal Study of CRS/HIPEC for Peritoneal Carcinomatoses

Prospective analysis of disease free after CRS/HIPEC for peritoneal carcinomatosis

Prospective analysis of overall survival after CRS/HIPEC for peritoneal carcinomatosis

Screening for acute renal insufficiency by measuring serum chemistry (serum creatinine (mg/dl) before as well as during the first 7 postoperative days

Screening for acute renal insufficiency by measuring serum chemistry (serum urea (mg/dl) before as well as during the first 7 days postoperative

Screening for acute renal insufficiency by measuring urine output (ml/24h) before as well as during the first 7 postoperative days

Longitudinal analysis of the microbial burden within samples will be quantified with droplet digital polymerase chain reaction. Bacterial 16S ribosomal RNA gene sequences will be amplified, sequenced, and analyzed in comparison to publicly available data obtained from healthy volunteers.

Longitudinal analysis of cellular immune responses in blood and peritoneal tissue by flow cytometry. Measuring frequency of NK cell populations within total lymphocyte population

Prospective analysis of quality of life after CRS/HIPEC for peritoneal carcinomatosis. Questionnaire-WHOQOL-BRE produces a quality of life profile. It is possible to derive four domain scores. There are also two items that are examined separately: question 1 asks about an individual's overall perception of quality of life and question 2 asks about an individual's overall perception of their health. The four domain scores denote an individual's perception of quality of life in each particular domain (Physical health (Score 7-35), Psychological (Score 6-30), Social relationships (Score 3-15), Environment (Score 8-40)). Domain scores are scaled in a positive direction (i.e. higher scores denote higher quality of life). The mean score of items within each domain is used to calculate the domain score transformed to 4-20 or 20-100.

Krankenhaus Barmherzige Brüder, Regensburg

University of Regensburg

Head of Surgery

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Rare Diseases

Ovarian Neoplasms

Ovarian Diseases

Endocrine Gland Neoplasms

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Ovarian Cancer

The group consists of patients of benign ovarian diseases and health conditions (eg infertility), who would accept the tests of pelvic microbiomes.

The group consists of patients of high grade serous carcinoma, who would accept the tests of pelvic microbiomes.

16s RNA analysis and microculture of discharges/flushing fluid from vagina, faces and fimbria end of fallopian tube

microbiomes

Lei Li, MD

Lan Zhu, MD

This case-control study aims to compare the pelvic microbiomes of benign ovarian diseases and ovarian malignancies by 16s RNA techniques and culture. Discharges/flushing fluid from vagina, faces and fimbria end of fallopian tube are collected from age and menopausal status matched patient before and during procedures of laparoscopies. The discharges/flushing fluid would be sent for 16s RNA analysis and microculture respectively, and the results would get self-contrasted comparison and case-control comparison.

Discharges/flushing fluid from vagina, faces and fimbria end of fallopian tube are going to sent for analysis of 16s RNA.

Pelvic Microbiomes of Benign and Malignant Ovarian Diseases

The Role of Pelvic Microbiomes During the Malignant Transformation of Benign Ovarian Diseases

We would share individual participant data to all other researchers

The difference of species of microorganism distribution according to 16s RNA sequencing analysis between control group and study group, and between different sampling sites in each arm

Difference of species distribution of microorganism according to microculture outcomes between control group and study group, and between different sampling sites in each arm

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Longitudinal Study of CRS/HIPEC for Peritoneal Carcinomatoses	NCT04108936	Peritoneal Carc...		18 Years - 80 Years	University of Regensburg
Pelvic Microbiomes of Benign and Malignant Ovarian Diseases	NCT03388996	Microbiota Ovarian Neoplas... Ribosome Altera...	microbiomes	-	Peking Union Medical College Hospital
Pelvic Microbiomes of Benign and Malignant Ovarian Diseases	NCT03388996	Microbiota Ovarian Neoplas... Ribosome Altera...	microbiomes	-	Peking Union Medical College Hospital
Longitudinal Study of CRS/HIPEC for Peritoneal Carcinomatoses	NCT04108936	Peritoneal Carc...		18 Years - 80 Years	University of Regensburg

Spots Global Cancer Trial Database for microbiomes

Every month we try and update this database with for microbiomes cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for microbiomes

Every month we try and update this database with for microbiomes cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for microbiomes cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.